EPO Meets with Novo Nordisk to Discuss Quality and Health-Related Activities

Summary

The European Patent Office (EPO) recently met with Novo Nordisk to discuss quality and health-related activities, including the Unitary Patent and the EPO Observatory's health-related initiatives.

Original source language: European Patent Office NewsOpen original release →

Add your company to Business Communicator

We monitor business sources and connect attention with companies, profiles and services available in Business Communicator.

Create a free company profile Explore businesses on Business Maps →

Create a free company profile →

Explore insights

Business insights →

Healthcare Business News Global Markets News Trade Regulation News Business Technology News Fintech for Business: Payments & Banking News Supply Chain News

Related business signals

Innovation & intellectual property · 10/20/2026

EPO meets with Zebra Technologies

Exchanges on patent strategy, quality of examination and unitary patent

Read summary →

Innovation & intellectual property · 10/23/2026

Determination of Regulatory Review Period for Purposes of Patent Extension; Correction of Notices-ANDEMBRY; ANZUPGO; ANKTIVA; BIZENGRI; BRINSUPRI; DAYVIGO

The source item contains limited metadata.

Read summary →

Innovation & intellectual property · 10/23/2026

Implementing the Guiding and Establishing National Innovation for U.S. Stablecoins Act for the issuance of Stablecoins by Entities Subject to the Jurisdiction of the Office of the Comptroller of the Currency

The Office of the Comptroller of the Currency (OCC) is issuing regulations implementing the Guiding and Establishing National Innovation for U.S. Stablecoins Act regarding the issuance of payment stablecoins and certain...

Read summary →

Innovation & intellectual property · 10/22/2026

Eason Technology's subsidiary granted patent for Industrial Park Smart Grid Dispatch System, supporting the company's business expansion into industrial scenarios

HONG KONG, Oct. 22, 2026 — Eason Technology Limited ("Eason" or the "Company") (NYSE American: DXF), a company engaged in real estate operation management and investment, and digital technology business,...

Read summary →

Innovation & intellectual property · 10/22/2026

Ping An Biomedical announces planned acquisition of three tumor cell-related medical technology patents to build a core oncology and biotech intellectual property portfolio

Ping An Biomedical (NASDAQ: PASW) signs LOI to acquire 3 tumor cell-related patents for $22.5M to build a core oncology and biotech IP portfolio.

Read summary →

Innovation & intellectual property · 10/22/2026

TFS HealthScience devoile sa nouvelle identité de marque mondiale (TFS Health) is the first and only scientifically available

The new identity is reflected in the way this ORC of Swedish origin works with the authorities of the biotechnology, pharmaceutical and medical technologies sectors: a radical honesty...

Read summary →